EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
The Clorox Company
EL7 Factor Analysis
How we score this
Overall33
Weak — below market medianContrarianF 3/8Better than 33% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
71
18.2x17.8xTop tier
▸
Growth
18
-5.4%▼7.1%Bottom tier
▸
Quality
78
33.4%▲4.5%Top tier
▸
Safety
46
2.8x▼2.6xAround median
▸
Capital Return
19
—2.12%Bottom tier
▸
Momentum
20
-10.6%▼2.9%Bottom tier
▸
Sentiment
68
11▲3Top tier
CLX

CLX The Clorox Company

The Clorox Company · NYSE
Market Closed
87.76
▼ ⁦-1.14%⁩ (-1.01)
Market Cap$10.7B
Beta0.54
52w Low52w High
84.70128.90
Last Week
⁦-6.91%⁩
Last Month
⁦-18.51%⁩
Last 3 Months
⁦-2.51%⁩
Last Year
⁦-26.23%⁩
Fair Value
Current price$88
Analyst target · 5 analysts
$98
⁦+12%⁩
See it undervalued
Range ⁦$83–$127⁩
vs
DCF (estimate)
$42
⁦-52%⁩
Sees it clearly overvalued
⁦7.9⁩% discount · ⁦8⁩% growth
Bottom lineThe two methods disagree — estimate range ⁦$42–$98⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener
Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$17/mo
Monthly plan
$29/mo

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 5 analysts setting price target
$100.11
⁦+14.1%⁩
Current Price $87.76·Median $98.00
Low
$83.00
High
$127.00
Current price
$87.76
Average target
$100.11
Street summary

Slight decline in consensus while dispersion remains high

The average price target remained at 100.11 with five analysts, unchanged over the last 7 days, but it declined by 1.69, or 1.66%, over the last 30 days compared with 101.8. The current range is between 83 and 127, versus a current price of 87.76, reflecting clear dispersion among estimates despite consensus remaining above the current price.

As of 2026-09-11
Revisions momentum · 30d
⁦-1.7%⁩
Average rating
★ 2.74
Hold
Analyst coverage
19
Buy conviction
5%
Rating activity · 30d
0↑ · 0↓
Target dispersion
50%
Wide
Analyst ratings over time19 analysts rating
1
14
2
2
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months2.80 → 2.74
Recent analyst moves
  • = Reiterate2026-09-11
    UBS
    Neutral
  • = Reiterate2026-08-04
    Barclays
    Underweight
  • = Reiterate2026-08-04
    UBS
    Neutral
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    18.21x
    4.61x36.85x
    Cheap
  • Forward P/E
    14.29x
    3.86x30.86x
    Near median
  • EV / EBITDA
    8.46x
    2.86x22.90x
    Cheap
  • FCF Yield
    3.8%
    -37.4%14.9%
    Strong
  • Revenue Growth YoY
    -5.4%
    -16.7%29.2%
    Below average
  • EPS Growth YoY
    -26.3%
    -135.4%136.3%
    Near median
  • Gross Margin
    42.3%
    9.2%67.5%
    Above average
  • ROIC
    33.4%
    -29.3%20.8%
    Exceptional
  • Net Debt / EBITDA
    2.80x
    0.61x4.86x
    Near median
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    —
    —
Financial Analysis
|

Stock Analysis

AI-generated
Based on 2026-08-03 data

Company Overview

The Clorox Company operates in consumer goods through brands and products including Clorox, Glad, Hidden Valley Ranch, Kingsford, and Fresh Step, in addition to health and professional hygiene businesses. The company generates revenue from the sale of cleaning and home care products, trash bags, food products, grilling products, and cat litter, while health and hygiene businesses represent more than 50% of its portfolio. The 2.25 billion dollar acquisition of GOJO Industries expanded the company’s presence in the professional hygiene market through Purell, a business-to-business operation with an established product base and stable cash flows.

In quarter 4 of fiscal year 2026, revenue reached 1.95 billion dollars and declined 2% year over year, despite exceeding the market expectations stated in the provided data. Gross margin fell to 42.3% from 45.2%, reflecting inflationary and supply chain cost pressures, while reported net margin was 8.7%. On a 2026 TTM basis, the company recorded revenue of 6.8 billion dollars, gross profit of 3.0 billion dollars, net income of 756 million dollars, and earnings per share of approximately 6.21 dollars.

Performance varied across the portfolio in fiscal year 2026; Home Care achieved eight consecutive quarters of share growth, and Pro and international businesses continued to record strong share growth, while Glad and Hidden Valley Ranch improved during quarter 4 of fiscal year 2026. In contrast, Fresh Step and the Litter segment remained below the outperformance level targeted by management, while Kingsford experienced seasonal weakness due to weather and retailers’ promotional decisions. The company ended fiscal year 2026 with consumption approximately stable in quarter 4 and an overall share decline of only one-tenth of a percentage point.

What's Driving the Stock

  • Clorox expects net sales growth of between 13% and 14% in fiscal year 2027, driven by the addition of GOJO and favorable comparisons related to the ERP system, while it expects organic sales to range only between stability and a slight increase.
  • The acquisition of GOJO Industries was valued at approximately 2.25 billion dollars, and the business exceeded its targets in quarter 4 of fiscal year 2026 and was accretive to earnings rather than dilutive; management expects mid-single-digit organic growth followed by mid- to high-single-digit growth for several years as revenue synergies emerge.
  • Demand and share indicators improved gradually during fiscal year 2026; consumption returned to stability in quarter 4, the June 2026 share exit rate approached stability, Home Care recorded eight consecutive quarters of share growth, and Glad and Hidden Valley Ranch regained momentum.
  • Innovation contribution as a percentage of sales doubled during fiscal year 2026, and fiscal year 2027 plans include product and packaging improvements, wellness-related Hidden Valley Ranch innovations such as avocado oil products, and the development of low-dust and lightweight Fresh Step products.
  • The ERP system implementation was completed, and management expects to begin realizing benefits from improved supply chain planning, inventory reduction, automation, and global business services during fiscal year 2027 and beyond; it also expects administrative expense productivity to exceed its inflation rate on a comparable basis.
  • The company targets free cash flow equivalent to 11% to 13% of sales in fiscal year 2027 and says that expected cash flows over 12 to 18 months will be used to repay short-term balances and commercial paper.

Buying & Selling Case

▲ Buying Case4 pts

  • +The forecast for net sales growth of between 13% and 14% in fiscal year 2027 provides clear growth leverage, with contributions from GOJO and Purell and improved comparisons related to the ERP transition, although expected organic growth is more conservative at stable to slightly higher.
  • +The GOJO acquisition had a stronger start than management’s assumptions, as the business exceeded quarter 4 of fiscal year 2026 targets and became accretive to earnings, and the company expects it to support adjusted earnings per share in fiscal year 2027, with mid- to high-single-digit growth after revenue synergies are realized.
  • +The recovery of distribution lost after the cyberattack and improved share for Home Care, Glad, and Hidden Valley Ranch support the prospect of an organic sales recovery; distribution is now above its post-attack level, while Home Care recorded eight consecutive quarters of share growth.
  • +The completion of the ERP system represents an opportunity to convert digital infrastructure investments into actual productivity in planning, execution, and automation, alongside a target for free cash flow equivalent to 11% to 13% of sales in fiscal year 2027.

▼ Selling Case6 pts

Valuation

The average analyst target is 100.11 dollars, within a wide range of 83 to 127 dollars, and the stock has a Neutral consensus rating; the average target is well below the top of the 52-week range of 128.9 dollars and close to the midpoint of the range extending between 84.7 and 128.9 dollars. The news indicates a price-to-earnings multiple of 21.7 times, a valuation that requires balancing reported sales growth of between 13% and 14% in fiscal year 2027 against nearly stable organic growth, an expected gross margin of approximately 42%, and inflation exceeding 200 million dollars.

HoldAnalyst target: $100.11(+14.1%)

Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.

FAQ

What is the primary growth driver for Clorox in fiscal year 2027?

Management expects net sales growth of between 13% and 14% in fiscal year 2027, but the organic portion is expected to be only stable to slightly higher. Most of the difference comes from the addition of GOJO and comparisons related to the ERP system implementation. Therefore, the acceleration in reported revenue depends largely on the portfolio and comparisons, rather than on a similar jump in the sales volume of Clorox’s existing businesses.

How does the GOJO and Purell acquisition change the profile of CLX?

Clorox paid approximately 2.25 billion dollars to acquire GOJO Industries, adding Purell and expanding its health and professional hygiene platform. The business exceeded its targets in quarter 4 of fiscal year 2026 and was accretive to earnings rather than dilutive, as management initially assumed. The company expects mid-single-digit growth for the business, rising to mid- or high-single-digit growth for several years as revenue synergies are realized, in addition to supporting adjusted earnings per share in fiscal year 2027.

Why are Clorox’s margins under pressure in fiscal year 2027?

The company expects inflation to exceed 200 million dollars in fiscal year 2027, compared with a historical range of between 75 and 100 million dollars. Pressures include commodities, energy, supplier costs, ocean freight, transportation, and logistics, with an assumption of an average Brent crude price of approximately 90 dollars per barrel. Therefore, management targets a gross margin of approximately 42% and does not expect to recover it fully during fiscal year 2027, despite productivity and selective pricing.

Earnings callEDGAR filings30-day newsInsider activity

Automated analysis for informational purposes only — not investment advice.

  • −Organic demand remains weak despite the strength of the reported growth figure; fiscal year 2027 guidance assumes only stable to slightly higher organic sales, with positive pricing and negative volume, after quarter 4 of fiscal year 2026 revenue declined 2% to 1.95 billion dollars.
  • −Inflation represents the largest direct financial pressure, as management expects more than 200 million dollars of commodity, transportation, freight, and logistics inflation in fiscal year 2027, more than double the historical range of 75 to 100 million dollars, with the impact concentrated in the first half of fiscal year 2027.
  • −The company expects a gross margin of approximately 42% in fiscal year 2027 and does not expect to recover the margin fully during the year, after it fell in quarter 4 of fiscal year 2026 to 42.3% from 45.2%. GOJO’s different business mix also reduces consolidated gross margin by approximately half a percentage point and increases post-acquisition administrative expenses by less than one percentage point.
  • −The brands face pressure from consumers seeking value and elevated competitive activity; Litter and Fresh Step remain in an early stage of remediation, with management acknowledging that the product had excessive dust and that a strong competitor continued to make progress, while new pricing at Glad could make share recovery more volatile.
  • −The GOJO acquisition increases financial and execution complexity, as administrative expenses in fiscal year 2027 include a one-time negative impact of approximately 40 basis points from transaction costs, while interest expense is estimated at approximately 210 million dollars and the company intends to use cash flow to repay short-term debt over 12 to 18 months.
  • −Linda Rendle informed the board of directors in May 2026 of her intention to step down from her position due to personal health challenges, and confirmed on the August 3, 2026 call that she remained Chair and Chief Executive Officer, was cancer-free, and continued to perform her duties. The board was conducting an external search for a new Chief Executive Officer, adding transition and execution risks during a period that coincides with the integration of GOJO and the recovery of margins and market share.
Has Clorox regained its market share after the operational disruptions?

The company fully recovered the distribution it lost after the cyberattack, and distribution was above its level following that event according to the August 3, 2026 call. Home Care achieved eight consecutive quarters of share growth, while Glad and Hidden Valley Ranch shares also improved during quarter 4 of fiscal year 2026. However, Litter and Fresh Step remain in an early stage of remediation, despite improvements to the product, packaging, and pricing and the development of lightweight and low-dust options.

What was the status of Clorox’s leadership according to the August 3, 2026 call?

Linda Rendle held the positions of Chair and Chief Executive Officer during the quarter 4 fiscal year 2026 earnings call. She explained that she informed the board of directors in May 2026 of her intention to step down due to personal health challenges, while confirming that she was cancer-free and continued to perform her duties. She also said that the board had retained an external search firm and that the search for a new Chief Executive Officer was progressing according to the schedule set by the board, without naming a successor in the provided data.

What is the status of CLX’s cash flow and distribution policy?

Clorox targets free cash flow equivalent to 11% to 13% of sales in fiscal year 2027, despite margin pressure in the first half. Management acknowledged that the dividend payout ratio of approximately 85% of net income is high, but described this as a transitional situation related to margin rebuilding. The company also intends to use cash flows generated over 12 to 18 months to repay short-term balances and commercial paper, while its commitment to supporting distributions remained unchanged according to the August 3, 2026 call.